# Malakoff Humanis

> Malakoff Humanis is a VC fund backing Genetics, Robotics and Health Care. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 2
- Last investment: Jan 2022
- Lead investor: 0%
- Last updated: Aug 2026

Malakoff Humanis is an investment Firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Genetics | 1 | 50% |
| Robotics | 1 | 50% |
| Health Care | 1 | 50% |
| Therapeutics | 1 | 50% |
| Biotechnology | 1 | 50% |

9 industries tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Wandercraft | Wandercraft develops autonomous walking exoskeletons and robotic systems designed to restore upright mobility to individuals with walking impairments. The company offers devices such as Atalante X, a hands‑free, self‑balancing exoskeleton used in rehabilitation centers, and a Personal Exoskeleton prototype that leverages AI‑driven balance tosupport walking in daily life. Their systems incorporate real‑time adaptive gait algorithms and powered joints to facilitate multidirectional movement and support early intensive rehabilitation. Wandercraft collaborates with healthcare institutions and has initiated clinical trials to evaluate safety and effectiveness in managing spinal cord injuries and stroke rehabilitation. | $45.3M | Series C | Jan 20, 2022 |  |
| Xenothera | Xenothera is a xenotherapy platform with embedded technology that renovates immunological treatments. Xenothera creates new therapeutic modes in numerous domains from immunomodulation to infectious diseases.Xenothera's technological platform is built on a double expertise of animal genetics and mastery of immunology processes. It renovatespassive immunotherapy by marketing a new generation of hyperimmune polyclonal sera.Xenothera’s platform ensures short-time development thanks to their mastery of the entire process, from animal genetics, choice of the immunogen, selection, and purification of interesting immunoglobulins, and access to market authorization in accelerated timescale. | $21.2M | Series C | Jun 29, 2021 |  |

2 of 2 investments shown.

## Co-investors
- [Malakoff Humanis](https://shizune.co/investors/profile/malakoff-humanis-f838) — VC Fund, 2 deals together
- [Anaxago](https://shizune.co/investors/profile/anaxago) — VC Fund, 1 deal together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 1 deal together
- [Cemag Invest](https://shizune.co/investors/profile/cemag-invest) — VC Fund, 1 deal together
- [Eurazeo](https://shizune.co/investors/profile/eurazeo-com) — VC Fund, 1 deal together
- [European Innovation Council](https://shizune.co/investors/profile/european-innovation-council) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Malakoff Humanis invest in?

Malakoff Humanis invests primarily in Genetics, Robotics and Health Care startups, most often at Series C stage. Most of the 2 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Malakoff Humanis last invest?

The most recent investment recorded for Malakoff Humanis closed in Jan 2022. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co